Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/5748

Full metadata record
DC FieldValueLanguage
dc.contributor.authorReis Filho, Jorge S.-
dc.contributor.authorMilanezi, Fernanda-
dc.contributor.authorSteele, D.-
dc.contributor.authorSavage, K.-
dc.contributor.authorSimpson, Pete T.-
dc.contributor.authorNesland, J. M.-
dc.contributor.authorPereira, Emílio M.-
dc.contributor.authorLakhani, Sunil R.-
dc.contributor.authorSchmitt, Fernando C.-
dc.date.accessioned2006-11-06T16:00:34Z-
dc.date.available2006-11-06T16:00:34Z-
dc.date.issued2006-07-
dc.identifier.citation"Histopathology". ISSN 0309-0167. 49:1 (July 2006) 10-21.eng
dc.identifier.issn0309-0167eng
dc.identifier.urihttp://hdl.handle.net/1822/5748-
dc.description.abstractRecently, an immunohistochemical panel comprising antibodies against HER2, estrogen receptor (ER), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5 ⁄ 6 was reported to identify basal-like breast carcinomas, as defined by cDNA microarrays. Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype. Methods and results: Sixty-five cases were retrieved from the pathology archives of the authors’ institutions and reviewed by three of the authors. Immunohistochemistry with antibodies for HER2, ER, EGFR, CK5 ⁄ 6, CK14 and p63 was performed according to standard methods. All but six cases (91%) showed the typical immunoprofile of basal-like tumours (ER– and HER2–, EGFR+ and ⁄ or CK5 ⁄ 6+). When CK14 and p63 were added to the panel, two additional cases could be classified as basal-like. The majority of MBCs lacked PR, except 4 ⁄ 19 (21%) carcinomas with squamous metaplasia. Conclusions: Our results demonstrate that MBCs show a basal-like phenotype, regardless of the type of metaplastic elements. Moreover, as these neoplasms frequently overexpress EGFR (57%), patients with MBC may benefit from treatment with anti-EGFR drugs.eng
dc.language.isoengeng
dc.publisherBlackwell Publishingpor
dc.rightsopenAccesseng
dc.subjectCarcinosarcomaeng
dc.subjectEpidermal growth factor receptor (HER1)eng
dc.subjectMyoepithelialeng
dc.subjectSarcomatoid carcinomaeng
dc.subjectImmunohistochemistryeng
dc.titleMetaplastic breast carcinomas are basal-like tumourseng
dc.typearticlepor
dc.peerreviewedyeseng
sdum.number1eng
sdum.pagination10–21eng
sdum.publicationstatuspublishedeng
sdum.volume49eng
oaire.citationStartPage10por
oaire.citationEndPage21por
oaire.citationIssue1por
oaire.citationVolume49por
dc.identifier.doi10.1111/j.1365-2559.2006.02467.xpor
dc.identifier.pmid16842242por
dc.subject.wosScience & Technologypor
sdum.journalHistopathologypor
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
Histopathology_Sérgio.pdf1,9 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID